Under
the direction of the late Carl P. Schaffner, Ph.D., professor
emeritus at the Waksman Institute of Rutgers University,
ROCK of Africa Foundation began assisting in development of new
medicine to treat victims of HIV/AIDS in Africa.
The vast majority of people infected with
the HIV virus in sub-Saharan Africa receive no medicine at
all to treat the virus. The obvious reason is cost.
Teams of researchers in the US and Africa are donating their
time to develop low cost medicines for treating disease in
the Third World.
ROCK of Africa Foundation has established
collaborative research relationships with researchers in the
United States, South Africa and Ghana, West Africa
Amphotericin B Methyl Ester (AME) is a patent free medication to treat HIV/AIDS
victims in the Third World. A derivative of
Amphotericin B, AME is a highly effective medication for treatment
of fungal disease.
Benefits of AME
-
PATENT-FREE
low cost medication treatment for HIV/AIDS patients in the
Third World Medication free of
patents, can legally be manufactured by any company.
Competitive manufacture is the key to lower cost.
Dual efficacy
In addition to fighting the HIV virus, AME is highly
effective in fighting fungal disease
which claims the lives of many AIDS patients.
Outpatient treatment from
Rural Clinics This is impossible
using parent compound Amphotericin B. Hospitalization
is required.
|